ArticleEuropean urology open science2024
Thresholds of Body Composition Changes Associated with Survival During Androgen Deprivation Therapy in Prostate Cancer.
Article in European urology open science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The impact of different exercise modalities on health-related quality of life in patients with prostate cancer undergoing androgen deprivation therapy: a systematic review and network meta-analysis.Frontiers in oncology · 2026Pooled it
- Dyadic Associations of Physical Activity, Diet Quality, and Body Mass Index in Black Prostate Cancer Survivors and their Spouses: An Actor-Partner Interdependence Model Analysis.Journal of racial and ethnic health disparities · 2025Article
- Prognostic value of body composition out of PSMA-PET/CT in prostate cancer patients undergoing PSMA-therapy.European journal of nuclear medicine and molecular imaging · 2025Article
- Androgen Deprivation Therapy-Induced Muscle Loss and Fat Gain Predict Cardiovascular Events in Prostate Cancer Patients.Journal of cachexia, sarcopenia and muscle · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Androgen deprivation therapy (ADT) is associated with reduced muscle and increased fat mass in patients with prostate cancer. However, the threshold for body composition changes associated with survival during ADT remains unclear. This study aimed to identify body composition change thresholds for all-cause mortality during ADT. Methods: We enrolled 538 patients with prostate cancer (332 and 206 in the derivation and external validation cohorts, respectively) who underwent radiotherapy and ADT at two tertiary centers. Computed tomography (CT) images at baseline and 6 mo after ADT initiation were retrieved for an analysis. Skeletal muscle index (SMI), subcutaneous adipose tissue index (SATI), and visceral adipose tissue index (VATI) were measured using CT at the L3 vertebral level. Optimal thresholds for body composition changes were determined using the Shapley Additive Explanations (SHAP) method and validated using a Cox proportional hazard model. Key findings and limitations: Changes in SMI, SATI, and VATI were the three most important features for predicting all-cause mortality. SMI change was inversely associated with the all-cause mortality risk, and changes in the SATI and VATI showed a U-shaped relationship with the all-cause mortality risk. SMI loss (≥4.0%), SATI gain (≥15.0%), and VATI gain (≥12.0%) were independently associated with an increased all-cause mortality risk (SMI loss: hazard ratio, 6.79, Conclusions and clinical implications: The thresholds determined in this study can help identify patients with considerable body composition changes after 6 mo of ADT and guide interventions to improve body composition. Patient summary: We identified muscle loss and increased adipose tissue thresholds associated with all-cause mortality during androgen deprivation therapy for men with prostate cancer. These thresholds can help guide interventions to improve body composition and potentially improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.